nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylprednisolone—CYP3A4—Temozolomide—malignant glioma	0.496	1	CbGbCtD
Methylprednisolone—Monoplegia—Carmustine—malignant glioma	0.039	0.0798	CcSEcCtD
Methylprednisolone—Hyperadrenocorticism—Temozolomide—malignant glioma	0.0377	0.0771	CcSEcCtD
Methylprednisolone—Abnormal behaviour—Temozolomide—malignant glioma	0.0156	0.032	CcSEcCtD
Methylprednisolone—Meningitis—Carmustine—malignant glioma	0.0156	0.0318	CcSEcCtD
Methylprednisolone—Opportunistic infection—Temozolomide—malignant glioma	0.0145	0.0296	CcSEcCtD
Methylprednisolone—Intracranial pressure increased—Carmustine—malignant glioma	0.0144	0.0295	CcSEcCtD
Methylprednisolone—Impaired healing—Carmustine—malignant glioma	0.0139	0.0285	CcSEcCtD
Methylprednisolone—Skin hyperpigmentation—Carmustine—malignant glioma	0.0101	0.0208	CcSEcCtD
Methylprednisolone—Embolism—Temozolomide—malignant glioma	0.00908	0.0186	CcSEcCtD
Methylprednisolone—Myopathy—Temozolomide—malignant glioma	0.00831	0.017	CcSEcCtD
Methylprednisolone—Necrosis—Carmustine—malignant glioma	0.00768	0.0157	CcSEcCtD
Methylprednisolone—Abscess—Carmustine—malignant glioma	0.00762	0.0156	CcSEcCtD
Methylprednisolone—Petechiae—Temozolomide—malignant glioma	0.00708	0.0145	CcSEcCtD
Methylprednisolone—Amenorrhoea—Temozolomide—malignant glioma	0.00663	0.0136	CcSEcCtD
Methylprednisolone—Leukocytosis—Carmustine—malignant glioma	0.00642	0.0131	CcSEcCtD
Methylprednisolone—Skin exfoliation—Carmustine—malignant glioma	0.00576	0.0118	CcSEcCtD
Methylprednisolone—Neuropathy—Carmustine—malignant glioma	0.00566	0.0116	CcSEcCtD
Methylprednisolone—Skin exfoliation—Temozolomide—malignant glioma	0.00556	0.0114	CcSEcCtD
Methylprednisolone—Neuropathy—Temozolomide—malignant glioma	0.00547	0.0112	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Carmustine—malignant glioma	0.00506	0.0104	CcSEcCtD
Methylprednisolone—Diabetes mellitus—Carmustine—malignant glioma	0.00503	0.0103	CcSEcCtD
Methylprednisolone—Thrombophlebitis—Temozolomide—malignant glioma	0.00489	0.01	CcSEcCtD
Methylprednisolone—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00486	0.00995	CcSEcCtD
Methylprednisolone—Injury—Carmustine—malignant glioma	0.00476	0.00975	CcSEcCtD
Methylprednisolone—Amnesia—Carmustine—malignant glioma	0.00466	0.00954	CcSEcCtD
Methylprednisolone—Amnesia—Temozolomide—malignant glioma	0.0045	0.00922	CcSEcCtD
Methylprednisolone—Affect lability—Temozolomide—malignant glioma	0.00416	0.00852	CcSEcCtD
Methylprednisolone—Mood swings—Temozolomide—malignant glioma	0.00401	0.0082	CcSEcCtD
Methylprednisolone—Muscular weakness—Carmustine—malignant glioma	0.00386	0.0079	CcSEcCtD
Methylprednisolone—Breast disorder—Temozolomide—malignant glioma	0.00382	0.00782	CcSEcCtD
Methylprednisolone—Muscular weakness—Temozolomide—malignant glioma	0.00373	0.00764	CcSEcCtD
Methylprednisolone—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.00373	0.00764	CcSEcCtD
Methylprednisolone—Abdominal distension—Temozolomide—malignant glioma	0.00368	0.00753	CcSEcCtD
Methylprednisolone—Sweating increased—Temozolomide—malignant glioma	0.00356	0.00729	CcSEcCtD
Methylprednisolone—Weight increased—Temozolomide—malignant glioma	0.00333	0.00681	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Carmustine—malignant glioma	0.00331	0.00677	CcSEcCtD
Methylprednisolone—Infestation NOS—Temozolomide—malignant glioma	0.00326	0.00667	CcSEcCtD
Methylprednisolone—Infestation—Temozolomide—malignant glioma	0.00326	0.00667	CcSEcCtD
Methylprednisolone—Neuropathy peripheral—Temozolomide—malignant glioma	0.0032	0.00654	CcSEcCtD
Methylprednisolone—Haemoglobin—Carmustine—malignant glioma	0.00304	0.00623	CcSEcCtD
Methylprednisolone—Haemorrhage—Carmustine—malignant glioma	0.00303	0.0062	CcSEcCtD
Methylprednisolone—Hallucination—Carmustine—malignant glioma	0.00301	0.00617	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Carmustine—malignant glioma	0.00298	0.00609	CcSEcCtD
Methylprednisolone—Haemoglobin—Temozolomide—malignant glioma	0.00294	0.00602	CcSEcCtD
Methylprednisolone—Haemorrhage—Temozolomide—malignant glioma	0.00293	0.00599	CcSEcCtD
Methylprednisolone—Visual impairment—Carmustine—malignant glioma	0.00292	0.00597	CcSEcCtD
Methylprednisolone—Hallucination—Temozolomide—malignant glioma	0.00291	0.00596	CcSEcCtD
Methylprednisolone—Connective tissue disorder—Temozolomide—malignant glioma	0.00288	0.00589	CcSEcCtD
Methylprednisolone—Eye disorder—Carmustine—malignant glioma	0.00283	0.00579	CcSEcCtD
Methylprednisolone—Visual impairment—Temozolomide—malignant glioma	0.00282	0.00577	CcSEcCtD
Methylprednisolone—Eye disorder—Temozolomide—malignant glioma	0.00274	0.0056	CcSEcCtD
Methylprednisolone—Cardiac disorder—Temozolomide—malignant glioma	0.00272	0.00556	CcSEcCtD
Methylprednisolone—Arrhythmia—Carmustine—malignant glioma	0.00271	0.00554	CcSEcCtD
Methylprednisolone—Angiopathy—Temozolomide—malignant glioma	0.00266	0.00543	CcSEcCtD
Methylprednisolone—Mental disorder—Carmustine—malignant glioma	0.00265	0.00543	CcSEcCtD
Methylprednisolone—Immune system disorder—Temozolomide—malignant glioma	0.00264	0.00541	CcSEcCtD
Methylprednisolone—Mediastinal disorder—Temozolomide—malignant glioma	0.00264	0.0054	CcSEcCtD
Methylprednisolone—Erythema—Carmustine—malignant glioma	0.00264	0.0054	CcSEcCtD
Methylprednisolone—Malnutrition—Carmustine—malignant glioma	0.00264	0.0054	CcSEcCtD
Methylprednisolone—Mental disorder—Temozolomide—malignant glioma	0.00256	0.00525	CcSEcCtD
Methylprednisolone—Erythema—Temozolomide—malignant glioma	0.00255	0.00521	CcSEcCtD
Methylprednisolone—Malnutrition—Temozolomide—malignant glioma	0.00255	0.00521	CcSEcCtD
Methylprednisolone—Ill-defined disorder—Temozolomide—malignant glioma	0.00236	0.00484	CcSEcCtD
Methylprednisolone—Angioedema—Temozolomide—malignant glioma	0.00233	0.00476	CcSEcCtD
Methylprednisolone—Malaise—Temozolomide—malignant glioma	0.0023	0.0047	CcSEcCtD
Methylprednisolone—Vertigo—Temozolomide—malignant glioma	0.00229	0.00468	CcSEcCtD
Methylprednisolone—Convulsion—Carmustine—malignant glioma	0.00228	0.00467	CcSEcCtD
Methylprednisolone—Hypertension—Carmustine—malignant glioma	0.00228	0.00466	CcSEcCtD
Methylprednisolone—Myalgia—Carmustine—malignant glioma	0.00224	0.00459	CcSEcCtD
Methylprednisolone—Anxiety—Carmustine—malignant glioma	0.00224	0.00458	CcSEcCtD
Methylprednisolone—Convulsion—Temozolomide—malignant glioma	0.00221	0.00452	CcSEcCtD
Methylprednisolone—Hypertension—Temozolomide—malignant glioma	0.0022	0.0045	CcSEcCtD
Methylprednisolone—Confusional state—Carmustine—malignant glioma	0.00217	0.00444	CcSEcCtD
Methylprednisolone—Arthralgia—Temozolomide—malignant glioma	0.00217	0.00444	CcSEcCtD
Methylprednisolone—Myalgia—Temozolomide—malignant glioma	0.00217	0.00444	CcSEcCtD
Methylprednisolone—Anxiety—Temozolomide—malignant glioma	0.00216	0.00442	CcSEcCtD
Methylprednisolone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.00215	0.00441	CcSEcCtD
Methylprednisolone—Discomfort—Temozolomide—malignant glioma	0.00214	0.00439	CcSEcCtD
Methylprednisolone—Infection—Carmustine—malignant glioma	0.00214	0.00437	CcSEcCtD
Methylprednisolone—Tachycardia—Carmustine—malignant glioma	0.0021	0.0043	CcSEcCtD
Methylprednisolone—Confusional state—Temozolomide—malignant glioma	0.0021	0.00429	CcSEcCtD
Methylprednisolone—Anaphylactic shock—Temozolomide—malignant glioma	0.00208	0.00426	CcSEcCtD
Methylprednisolone—Infection—Temozolomide—malignant glioma	0.00207	0.00423	CcSEcCtD
Methylprednisolone—Nervous system disorder—Temozolomide—malignant glioma	0.00204	0.00417	CcSEcCtD
Methylprednisolone—Skin disorder—Temozolomide—malignant glioma	0.00202	0.00413	CcSEcCtD
Methylprednisolone—Hypotension—Carmustine—malignant glioma	0.00201	0.00411	CcSEcCtD
Methylprednisolone—Hyperhidrosis—Temozolomide—malignant glioma	0.00201	0.00411	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Carmustine—malignant glioma	0.00196	0.00401	CcSEcCtD
Methylprednisolone—Insomnia—Carmustine—malignant glioma	0.00195	0.00398	CcSEcCtD
Methylprednisolone—Paraesthesia—Carmustine—malignant glioma	0.00193	0.00395	CcSEcCtD
Methylprednisolone—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.00189	0.00388	CcSEcCtD
Methylprednisolone—Insomnia—Temozolomide—malignant glioma	0.00188	0.00385	CcSEcCtD
Methylprednisolone—Paraesthesia—Temozolomide—malignant glioma	0.00187	0.00382	CcSEcCtD
Methylprednisolone—Dyspepsia—Temozolomide—malignant glioma	0.00183	0.00375	CcSEcCtD
Methylprednisolone—Fatigue—Temozolomide—malignant glioma	0.00179	0.00367	CcSEcCtD
Methylprednisolone—Feeling abnormal—Carmustine—malignant glioma	0.00177	0.00363	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Carmustine—malignant glioma	0.00176	0.0036	CcSEcCtD
Methylprednisolone—Feeling abnormal—Temozolomide—malignant glioma	0.00171	0.00351	CcSEcCtD
Methylprednisolone—Abdominal pain—Carmustine—malignant glioma	0.0017	0.00348	CcSEcCtD
Methylprednisolone—Gastrointestinal pain—Temozolomide—malignant glioma	0.0017	0.00348	CcSEcCtD
Methylprednisolone—Urticaria—Temozolomide—malignant glioma	0.00165	0.00338	CcSEcCtD
Methylprednisolone—Abdominal pain—Temozolomide—malignant glioma	0.00164	0.00336	CcSEcCtD
Methylprednisolone—Hypersensitivity—Carmustine—malignant glioma	0.00159	0.00324	CcSEcCtD
Methylprednisolone—Asthenia—Carmustine—malignant glioma	0.00154	0.00316	CcSEcCtD
Methylprednisolone—Hypersensitivity—Temozolomide—malignant glioma	0.00153	0.00314	CcSEcCtD
Methylprednisolone—Asthenia—Temozolomide—malignant glioma	0.00149	0.00305	CcSEcCtD
Methylprednisolone—Diarrhoea—Carmustine—malignant glioma	0.00147	0.00301	CcSEcCtD
Methylprednisolone—Pruritus—Temozolomide—malignant glioma	0.00147	0.00301	CcSEcCtD
Methylprednisolone—Dizziness—Carmustine—malignant glioma	0.00142	0.00291	CcSEcCtD
Methylprednisolone—Diarrhoea—Temozolomide—malignant glioma	0.00142	0.00291	CcSEcCtD
Methylprednisolone—Dizziness—Temozolomide—malignant glioma	0.00137	0.00281	CcSEcCtD
Methylprednisolone—Vomiting—Carmustine—malignant glioma	0.00137	0.0028	CcSEcCtD
Methylprednisolone—Rash—Carmustine—malignant glioma	0.00136	0.00278	CcSEcCtD
Methylprednisolone—Dermatitis—Carmustine—malignant glioma	0.00136	0.00277	CcSEcCtD
Methylprednisolone—Headache—Carmustine—malignant glioma	0.00135	0.00276	CcSEcCtD
Methylprednisolone—Vomiting—Temozolomide—malignant glioma	0.00132	0.00271	CcSEcCtD
Methylprednisolone—Rash—Temozolomide—malignant glioma	0.00131	0.00268	CcSEcCtD
Methylprednisolone—Dermatitis—Temozolomide—malignant glioma	0.00131	0.00268	CcSEcCtD
Methylprednisolone—Headache—Temozolomide—malignant glioma	0.0013	0.00267	CcSEcCtD
Methylprednisolone—Nausea—Carmustine—malignant glioma	0.00128	0.00262	CcSEcCtD
Methylprednisolone—Nausea—Temozolomide—malignant glioma	0.00124	0.00253	CcSEcCtD
Methylprednisolone—Triamcinolone—BCHE—malignant glioma	0.000468	0.379	CrCbGaD
Methylprednisolone—CYP3A4—Liver X Receptor Pathway—CYP2B6—malignant glioma	0.000466	0.0329	CbGpPWpGaD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—NF1—malignant glioma	0.000373	0.0263	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—POR—malignant glioma	0.000315	0.0222	CbGpPWpGaD
Methylprednisolone—NR3C1—Signaling events mediated by HDAC Class II—YWHAE—malignant glioma	0.000303	0.0214	CbGpPWpGaD
Methylprednisolone—ABCB1—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	0.000298	0.021	CbGpPWpGaD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2B6—malignant glioma	0.000284	0.02	CbGpPWpGaD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—TFRC—malignant glioma	0.000283	0.02	CbGpPWpGaD
Methylprednisolone—Dexamethasone—CYP2B6—malignant glioma	0.000273	0.221	CrCbGaD
Methylprednisolone—CYP3A4—Xenobiotics—CYP2B6—malignant glioma	0.000268	0.0189	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PIM1—malignant glioma	0.000265	0.0187	CbGpPWpGaD
Methylprednisolone—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—malignant glioma	0.000263	0.0185	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MYB—malignant glioma	0.000248	0.0175	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—SOX2—malignant glioma	0.000245	0.0173	CbGpPWpGaD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—PPARG—malignant glioma	0.00024	0.0169	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—RUNX3—malignant glioma	0.000239	0.0169	CbGpPWpGaD
Methylprednisolone—CYP3A4—Xenobiotics—CYP2C18—malignant glioma	0.000232	0.0164	CbGpPWpGaD
Methylprednisolone—NR3C1—BMAL1:CLOCK,NPAS2 activates circadian gene expression—NCOR1—malignant glioma	0.000221	0.0156	CbGpPWpGaD
Methylprednisolone—CYP3A4—Irinotecan Pathway—BCHE—malignant glioma	0.000218	0.0153	CbGpPWpGaD
Methylprednisolone—Triamcinolone—PTGS2—malignant glioma	0.000216	0.174	CrCbGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—ASMT—malignant glioma	0.000193	0.0136	CbGpPWpGaD
Methylprednisolone—CYP3A4—Constitutive Androstane Receptor Pathway—CYP2B6—malignant glioma	0.000184	0.013	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—NDRG1—malignant glioma	0.000178	0.0125	CbGpPWpGaD
Methylprednisolone—Betamethasone—PTGS2—malignant glioma	0.000177	0.143	CrCbGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2B6—malignant glioma	0.000175	0.0124	CbGpPWpGaD
Methylprednisolone—NR3C1—Circadian Clock—NCOR1—malignant glioma	0.000161	0.0113	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptors—PPARG—malignant glioma	0.000155	0.0109	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—GDNF—malignant glioma	0.000154	0.0109	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—GJA1—malignant glioma	0.000153	0.0108	CbGpPWpGaD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—F2—malignant glioma	0.000149	0.0105	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—RUNX3—malignant glioma	0.000141	0.00998	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IL12A—malignant glioma	0.000141	0.00993	CbGpPWpGaD
Methylprednisolone—NR3C1—Circadian Clock—HIF1A—malignant glioma	0.000136	0.00956	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—FLT1—malignant glioma	0.000132	0.00934	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—MYB—malignant glioma	0.000131	0.00921	CbGpPWpGaD
Methylprednisolone—NR3C1—Transcription factor regulation in adipogenesis—TNF—malignant glioma	0.000127	0.00899	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—SOX2—malignant glioma	0.000126	0.00889	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDKN2B—malignant glioma	0.000124	0.00877	CbGpPWpGaD
Methylprednisolone—NR3C1—Nuclear Receptor transcription pathway—PPARG—malignant glioma	0.000122	0.00864	CbGpPWpGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—CYP2C18—malignant glioma	0.000119	0.00841	CbGpPWpGaD
Methylprednisolone—CYP3A4—Irinotecan Pathway—APC—malignant glioma	0.000118	0.00833	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—NCOR1—malignant glioma	0.000118	0.00832	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—HLA-A—malignant glioma	0.000117	0.00824	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—HIF1A—malignant glioma	0.000112	0.00788	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2B6—malignant glioma	0.000111	0.00784	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—TFRC—malignant glioma	0.00011	0.00775	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP2B6—malignant glioma	0.00011	0.00774	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—HLA-C—malignant glioma	0.000104	0.00734	CbGpPWpGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—NOTCH1—malignant glioma	0.000103	0.00727	CbGpPWpGaD
Methylprednisolone—Dexamethasone—PTGS2—malignant glioma	0.000103	0.0831	CrCbGaD
Methylprednisolone—NR3C1—Endoderm Differentiation—APC—malignant glioma	0.000101	0.00711	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—NTRK2—malignant glioma	9.8e-05	0.00691	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—YWHAE—malignant glioma	9.8e-05	0.00691	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of Androgen receptor activity—MDM2—malignant glioma	9.69e-05	0.00683	CbGpPWpGaD
Methylprednisolone—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2C18—malignant glioma	9.64e-05	0.0068	CbGpPWpGaD
Methylprednisolone—CYP3A4—Oxidation by Cytochrome P450—CYP2C18—malignant glioma	9.51e-05	0.00671	CbGpPWpGaD
Methylprednisolone—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	9.1e-05	0.00642	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—PDGFRA—malignant glioma	9.08e-05	0.0064	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2B6—malignant glioma	9.01e-05	0.00636	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IL12B—malignant glioma	8.85e-05	0.00624	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—NCOR1—malignant glioma	8.08e-05	0.0057	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—GJA1—malignant glioma	8.06e-05	0.00568	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—STMN1—malignant glioma	8.02e-05	0.00565	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CDKN2A—malignant glioma	8e-05	0.00564	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—CYP2C18—malignant glioma	7.81e-05	0.00551	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—IFNG—malignant glioma	7.8e-05	0.0055	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—CXCL8—malignant glioma	7.25e-05	0.00511	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—HES1—malignant glioma	7.03e-05	0.00496	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—IL2—malignant glioma	6.93e-05	0.00489	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—IFNG—malignant glioma	6.87e-05	0.00485	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—MDM2—malignant glioma	6.83e-05	0.00482	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—HIF1A—malignant glioma	6.81e-05	0.0048	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—TERT—malignant glioma	6.58e-05	0.00464	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MMP9—malignant glioma	6.56e-05	0.00463	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—PTEN—malignant glioma	6.52e-05	0.0046	CbGpPWpGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—CAT—malignant glioma	6.5e-05	0.00459	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—CXCL8—malignant glioma	6.39e-05	0.00451	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—HIF1A—malignant glioma	6.29e-05	0.00444	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—PDGFRA—malignant glioma	6.19e-05	0.00437	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—HLA-B—malignant glioma	6.15e-05	0.00434	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—IL2—malignant glioma	6.11e-05	0.00431	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PLK1—malignant glioma	6.08e-05	0.00429	CbGpPWpGaD
Methylprednisolone—CYP3A4—Phase 1 - Functionalization of compounds—PTGS1—malignant glioma	5.92e-05	0.00418	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—HIF1A—malignant glioma	5.89e-05	0.00415	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—PPARG—malignant glioma	5.79e-05	0.00409	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—WT1—malignant glioma	5.76e-05	0.00406	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—HLA-A—malignant glioma	5.7e-05	0.00402	CbGpPWpGaD
Methylprednisolone—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—malignant glioma	5.61e-05	0.00395	CbGpPWpGaD
Methylprednisolone—NR3C1—FOXA2 and FOXA3 transcription factor networks—AKT1—malignant glioma	5.45e-05	0.00384	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—MYC—malignant glioma	5.42e-05	0.00382	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PML—malignant glioma	5.13e-05	0.00362	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—MYC—malignant glioma	4.82e-05	0.0034	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—CD80—malignant glioma	4.81e-05	0.00339	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP2B6—malignant glioma	4.79e-05	0.00338	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP2B6—malignant glioma	4.72e-05	0.00333	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TOP2A—malignant glioma	4.7e-05	0.00331	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—COX8A—malignant glioma	4.68e-05	0.0033	CbGpPWpGaD
Methylprednisolone—NR3C1—AP-1 transcription factor network—TP53—malignant glioma	4.45e-05	0.00314	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—FTH1—malignant glioma	4.28e-05	0.00302	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—CYP2C18—malignant glioma	4.15e-05	0.00293	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—CYP2C18—malignant glioma	4.09e-05	0.00289	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NOTCH3—malignant glioma	4.04e-05	0.00285	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—TP53—malignant glioma	3.92e-05	0.00277	CbGpPWpGaD
Methylprednisolone—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—malignant glioma	3.87e-05	0.00273	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—CXCL8—malignant glioma	3.82e-05	0.00269	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—RTEL1—malignant glioma	3.82e-05	0.00269	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IFNG—malignant glioma	3.8e-05	0.00268	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—ATP1B2—malignant glioma	3.74e-05	0.00264	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—IL1B—malignant glioma	3.66e-05	0.00258	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—CASP3—malignant glioma	3.66e-05	0.00258	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—malignant glioma	3.65e-05	0.00258	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—APOD—malignant glioma	3.64e-05	0.00257	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NOTCH2—malignant glioma	3.62e-05	0.00255	CbGpPWpGaD
Methylprednisolone—CYP3A4—Tryptophan metabolism—MDM2—malignant glioma	3.59e-05	0.00253	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—STAT3—malignant glioma	3.55e-05	0.00251	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—CXCL8—malignant glioma	3.54e-05	0.00249	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—malignant glioma	3.39e-05	0.00239	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IL1B—malignant glioma	3.39e-05	0.00239	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—CASP3—malignant glioma	3.38e-05	0.00239	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—IL2—malignant glioma	3.38e-05	0.00238	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—malignant glioma	3.36e-05	0.00237	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTT1—malignant glioma	3.36e-05	0.00237	CbGpPWpGaD
Methylprednisolone—NR3C1—Regulation of nuclear SMAD2/3 signaling—AKT1—malignant glioma	3.34e-05	0.00236	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—malignant glioma	3.32e-05	0.00234	CbGpPWpGaD
Methylprednisolone—NR3C1—Glucocorticoid receptor regulatory network—AKT1—malignant glioma	3.31e-05	0.00234	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—PTGS1—malignant glioma	3.15e-05	0.00222	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—CDKN2B—malignant glioma	3.11e-05	0.00219	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—VEGFA—malignant glioma	3.1e-05	0.00219	CbGpPWpGaD
Methylprednisolone—NR3C1—Adipogenesis—TNF—malignant glioma	3.08e-05	0.00217	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PDGFRA—malignant glioma	3.06e-05	0.00216	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NCOR1—malignant glioma	2.95e-05	0.00208	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—VEGFA—malignant glioma	2.87e-05	0.00203	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—DNMT3B—malignant glioma	2.76e-05	0.00195	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—FGFR1—malignant glioma	2.73e-05	0.00193	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—HIST1H3B—malignant glioma	2.68e-05	0.00189	CbGpPWpGaD
Methylprednisolone—NR3C1—SIDS Susceptibility Pathways—TNF—malignant glioma	2.66e-05	0.00188	CbGpPWpGaD
Methylprednisolone—ABCB1—Allograft Rejection—TNF—malignant glioma	2.46e-05	0.00174	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—malignant glioma	2.45e-05	0.00173	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—APC—malignant glioma	2.37e-05	0.00167	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—RTEL1—malignant glioma	2.35e-05	0.00166	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—malignant glioma	2.34e-05	0.00165	CbGpPWpGaD
Methylprednisolone—CYP3A4—Biological oxidations—GSTP1—malignant glioma	2.33e-05	0.00164	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metapathway biotransformation—GSTP1—malignant glioma	2.29e-05	0.00162	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—NOTCH1—malignant glioma	2.24e-05	0.00158	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—COX8A—malignant glioma	2.19e-05	0.00155	CbGpPWpGaD
Methylprednisolone—ABCB1—HIF-1-alpha transcription factor network—AKT1—malignant glioma	2.12e-05	0.00149	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—PPARG—malignant glioma	2.11e-05	0.00149	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—H3F3A—malignant glioma	2.07e-05	0.00146	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—malignant glioma	1.99e-05	0.00141	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NOTCH3—malignant glioma	1.94e-05	0.00137	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—malignant glioma	1.89e-05	0.00134	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—malignant glioma	1.87e-05	0.00132	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—ASMT—malignant glioma	1.86e-05	0.00132	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—TFRC—malignant glioma	1.86e-05	0.00131	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—malignant glioma	1.86e-05	0.00131	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—malignant glioma	1.84e-05	0.0013	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—malignant glioma	1.8e-05	0.00127	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—BCAN—malignant glioma	1.75e-05	0.00124	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NOTCH2—malignant glioma	1.74e-05	0.00123	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC5A5—malignant glioma	1.71e-05	0.00121	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—malignant glioma	1.67e-05	0.00118	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—SLC6A3—malignant glioma	1.63e-05	0.00115	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—malignant glioma	1.57e-05	0.00111	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—CDKN2B—malignant glioma	1.5e-05	0.00106	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NCOR1—malignant glioma	1.42e-05	0.001	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—malignant glioma	1.42e-05	0.001	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—IDH2—malignant glioma	1.41e-05	0.000997	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—COX8A—malignant glioma	1.35e-05	0.000953	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP2B6—malignant glioma	1.33e-05	0.000937	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—malignant glioma	1.3e-05	0.00092	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—malignant glioma	1.28e-05	0.0009	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—IDH1—malignant glioma	1.22e-05	0.000857	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—malignant glioma	1.21e-05	0.000857	CbGpPWpGaD
Methylprednisolone—NR3C1—Generic Transcription Pathway—MYC—malignant glioma	1.21e-05	0.00085	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—malignant glioma	1.2e-05	0.00085	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SPHK1—malignant glioma	1.18e-05	0.000829	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CYP2C18—malignant glioma	1.15e-05	0.000813	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—ASMT—malignant glioma	1.15e-05	0.00081	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—malignant glioma	1.11e-05	0.000781	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—BCAN—malignant glioma	1.08e-05	0.000762	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—NOTCH1—malignant glioma	1.08e-05	0.000761	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—malignant glioma	1.07e-05	0.000755	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—PPARG—malignant glioma	1.02e-05	0.000718	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTT1—malignant glioma	9.32e-06	0.000657	CbGpPWpGaD
Methylprednisolone—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—malignant glioma	9.04e-06	0.000638	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS1—malignant glioma	8.73e-06	0.000616	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—IDH2—malignant glioma	8.71e-06	0.000614	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP2B6—malignant glioma	8.19e-06	0.000577	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—BCHE—malignant glioma	8.12e-06	0.000573	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—SLC5A5—malignant glioma	8.02e-06	0.000566	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—IDH1—malignant glioma	7.49e-06	0.000528	CbGpPWpGaD
Methylprednisolone—ABCB1—Transmembrane transport of small molecules—RAF1—malignant glioma	7.38e-06	0.000521	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SPHK1—malignant glioma	7.25e-06	0.000511	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CYP2C18—malignant glioma	7.1e-06	0.000501	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—GSTP1—malignant glioma	6.46e-06	0.000456	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CAT—malignant glioma	6.28e-06	0.000443	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—NCOR1—malignant glioma	5.94e-06	0.000419	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—MYC—malignant glioma	5.81e-06	0.000409	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTT1—malignant glioma	5.74e-06	0.000405	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS1—malignant glioma	5.38e-06	0.000379	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—BCHE—malignant glioma	5e-06	0.000353	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—SLC5A5—malignant glioma	4.94e-06	0.000348	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—CAV1—malignant glioma	4.84e-06	0.000341	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PIK3CG—malignant glioma	4.41e-06	0.000311	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PPARG—malignant glioma	4.25e-06	0.0003	CbGpPWpGaD
Methylprednisolone—NR3C1—Gene Expression—AKT1—malignant glioma	4.03e-06	0.000284	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—GSTP1—malignant glioma	3.98e-06	0.000281	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PIK3CD—malignant glioma	3.87e-06	0.000273	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CAT—malignant glioma	3.87e-06	0.000273	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—NCOR1—malignant glioma	3.66e-06	0.000258	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PIK3CB—malignant glioma	3.38e-06	0.000238	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTGS2—malignant glioma	3.35e-06	0.000236	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—CAV1—malignant glioma	2.98e-06	0.00021	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PTEN—malignant glioma	2.92e-06	0.000206	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PIK3CG—malignant glioma	2.72e-06	0.000192	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PPARG—malignant glioma	2.62e-06	0.000185	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PIK3CD—malignant glioma	2.39e-06	0.000168	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PIK3CB—malignant glioma	2.08e-06	0.000147	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTGS2—malignant glioma	2.06e-06	0.000145	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—PIK3CA—malignant glioma	2.06e-06	0.000145	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PTEN—malignant glioma	1.8e-06	0.000127	CbGpPWpGaD
Methylprednisolone—ABCB1—Metabolism—AKT1—malignant glioma	1.68e-06	0.000119	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—PIK3CA—malignant glioma	1.27e-06	8.95e-05	CbGpPWpGaD
Methylprednisolone—CYP3A4—Metabolism—AKT1—malignant glioma	1.04e-06	7.31e-05	CbGpPWpGaD
